372 related articles for article (PubMed ID: 32716480)
1. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
Lizak N; Malpas CB; Sharmin S; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Lugaresi A; Duquette P; Girard M; Prat A; Larochelle C; Trojano M; Grand'Maison F; Grammond P; Sola P; Ferraro D; Hupperts R; Bergamaschi R; Boz C; Van Pesch V; Spitaleri D; Terzi M; Kalincik T;
JAMA Neurol; 2020 Nov; 77(11):1398-1407. PubMed ID: 32716480
[TBL] [Abstract][Full Text] [Related]
2. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
[TBL] [Abstract][Full Text] [Related]
3. Risk of secondary progressive multiple sclerosis after early worsening of disability.
Dzau W; Sharmin S; Patti F; Izquierdo G; Eichau S; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Ozakbas S; Gerlach O; Boz C; Grammond P; Terzi M; Amato MP; La Spitaleri D; Ramo-Tello C; Maimone D; Cartechini E; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Iuliano G; Soysal A; Kalincik T
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):984-991. PubMed ID: 37414538
[TBL] [Abstract][Full Text] [Related]
4. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
[TBL] [Abstract][Full Text] [Related]
5. Management of secondary-progressive multiple sclerosis.
Giovannoni G
CNS Drugs; 2004; 18(10):653-69. PubMed ID: 15270594
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
Lorscheider J; Jokubaitis VG; Spelman T; Izquierdo G; Lugaresi A; Havrdova E; Horakova D; Trojano M; Duquette P; Girard M; Prat A; Grand'Maison F; Grammond P; Pucci E; Boz C; Sola P; Ferraro D; Spitaleri D; Lechner-Scott J; Terzi M; Van Pesch V; Iuliano G; Bergamaschi R; Ramo-Tello C; Granella F; Oreja-Guevara C; Butzkueven H; Kalincik T;
Neurology; 2017 Sep; 89(10):1050-1059. PubMed ID: 28794248
[TBL] [Abstract][Full Text] [Related]
7. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
[TBL] [Abstract][Full Text] [Related]
8. Risk of secondary progressive multiple sclerosis: A longitudinal study.
Fambiatos A; Jokubaitis V; Horakova D; Kubala Havrdova E; Trojano M; Prat A; Girard M; Duquette P; Lugaresi A; Izquierdo G; Grand'Maison F; Grammond P; Sola P; Ferraro D; Alroughani R; Terzi M; Hupperts R; Boz C; Lechner-Scott J; Pucci E; Bergamaschi R; Van Pesch V; Ozakbas S; Granella F; Turkoglu R; Iuliano G; Spitaleri D; McCombe P; Solaro C; Slee M; Ampapa R; Soysal A; Petersen T; Sanchez-Menoyo JL; Verheul F; Prevost J; Sidhom Y; Van Wijmeersch B; Vucic S; Cristiano E; Saladino ML; Deri N; Barnett M; Olascoaga J; Moore F; Skibina O; Gray O; Fragoso Y; Yamout B; Shaw C; Singhal B; Shuey N; Hodgkinson S; Altintas A; Al-Harbi T; Csepany T; Taylor B; Hughes J; Jun JK; van der Walt A; Spelman T; Butzkueven H; Kalincik T
Mult Scler; 2020 Jan; 26(1):79-90. PubMed ID: 31397221
[TBL] [Abstract][Full Text] [Related]
9. Impact of multiple sclerosis relapses on progression diminishes with time.
Tremlett H; Yousefi M; Devonshire V; Rieckmann P; Zhao Y;
Neurology; 2009 Nov; 73(20):1616-23. PubMed ID: 19890070
[TBL] [Abstract][Full Text] [Related]
10. Disability accrual in primary and secondary progressive multiple sclerosis.
Harding-Forrester S; Roos I; Nguyen AL; Malpas CB; Diouf I; Moradi N; Sharmin S; Izquierdo G; Eichau S; Patti F; Horakova D; Kubala Havrdova E; Prat A; Girard M; Duquette P; Grand'Maison F; Onofrj M; Lugaresi A; Grammond P; Ozakbas S; Amato MP; Gerlach O; Sola P; Ferraro D; Buzzard K; Skibina O; Lechner-Scott J; Alroughani R; Boz C; Van Pesch V; Cartechini E; Terzi M; Maimone D; Ramo-Tello C; Yamout B; Khoury SJ; La Spitaleri D; Sa MJ; Blanco Y; Granella F; Slee M; Butler E; Sidhom Y; Gouider R; Bergamaschi R; Karabudak R; Ampapa R; Sánchez-Menoyo JL; Prevost J; Castillo-Trivino T; McCombe PA; Macdonell R; Laureys G; Van Hijfte L; Oh J; Altintas A; de Gans K; Turkoglu R; van der Walt A; Butzkueven H; Vucic S; Barnett M; Cristiano E; Hodgkinson S; Iuliano G; Kappos L; Kuhle J; Shaygannejad V; Soysal A; Weinstock-Guttman B; Van Wijmeersch B; Kalincik T;
J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):707-717. PubMed ID: 37068931
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
12. Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.
Ahrweiller K; Rousseau C; Le Page E; Bajeux E; Leray E; Michel L; Edan G; Kerbrat A
Mult Scler; 2020 Jul; 26(8):924-935. PubMed ID: 31094285
[TBL] [Abstract][Full Text] [Related]
13. Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Roos I; Hughes S; McDonnell G; Malpas CB; Sharmin S; Boz C; Alroughani R; Ozakbas S; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Lechner-Scott J; Kuhle J; Terzi M; Laureys G; Van Hijfte L; John N; Grammond P; Grand'Maison F; Soysal A; Jensen AV; Rasmussen PV; Svendsen KB; Barzinji I; Nielsen HH; Sejbæk T; Prakash S; Stilund MLM; Weglewski A; Issa NM; Kant M; Sellebjerg F; Gray O; Magyari M; Kalincik T;
JAMA Neurol; 2023 Aug; 80(8):789-797. PubMed ID: 37307006
[TBL] [Abstract][Full Text] [Related]
14. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
Iaffaldano P; Lucisano G; Patti F; Brescia Morra V; De Luca G; Lugaresi A; Zaffaroni M; Inglese M; Salemi G; Cocco E; Conte A; Ferraro D; Galgani S; Bergamaschi R; Pozzilli C; Salvetti M; Lus G; Rovaris M; Maniscalco GT; Logullo FO; Paolicelli D; Achille M; Marrazzo G; Lovato V; Comi G; Filippi M; Amato MP; Trojano M;
Mult Scler; 2021 Mar; 27(3):430-438. PubMed ID: 33210986
[TBL] [Abstract][Full Text] [Related]
15. Secondary Progressive Multiple Sclerosis: New Insights.
Cree BAC; Arnold DL; Chataway J; Chitnis T; Fox RJ; Pozo Ramajo A; Murphy N; Lassmann H
Neurology; 2021 Aug; 97(8):378-388. PubMed ID: 34088878
[TBL] [Abstract][Full Text] [Related]
16. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
17. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
Kopp TI; Bramow S; Illes Z; Kant M; Kristensen C; Rasmussen PV; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2021 Nov; 56():103319. PubMed ID: 34666241
[TBL] [Abstract][Full Text] [Related]
18. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
Scalfari A; Neuhaus A; Degenhardt A; Rice GP; Muraro PA; Daumer M; Ebers GC
Brain; 2010 Jul; 133(Pt 7):1914-29. PubMed ID: 20534650
[TBL] [Abstract][Full Text] [Related]
19. Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
Roos I; Leray E; Casey R; Horakova D; Havrdova E; Izquierdo G; Madueño SE; Patti F; Edan G; Debouverie M; Pelletier J; Ozakbas S; Amato MP; Clavelou P; Grammond P; Boz C; Buzzard K; Skibina O; Ciron J; Gerlach O; Grand'Maison F; Lechner-Scott J; Malpas C; Butzkueven H; Vukusic S; Kalincik T;
Neurology; 2021 Aug; 97(9):e869-e880. PubMed ID: 34193589
[TBL] [Abstract][Full Text] [Related]
20. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Sharmin S; Roos I; Simpson-Yap S; Malpas C; Sánchez MM; Ozakbas S; Horakova D; Havrdova EK; Patti F; Alroughani R; Izquierdo G; Eichau S; Boz C; Zakaria M; Onofrj M; Lugaresi A; Weinstock-Guttman B; Prat A; Girard M; Duquette P; Terzi M; Amato MP; Karabudak R; Grand'Maison F; Khoury SJ; Grammond P; Lechner-Scott J; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Turkoglu R; Altintas A; Maimone D; Kermode A; Shalaby N; Pesch VV; Butler E; Sidhom Y; Gouider R; Mrabet S; Gerlach O; Soysal A; Barnett M; Kuhle J; Hughes S; Sa MJ; Hodgkinson S; Oreja-Guevara C; Ampapa R; Petersen T; Ramo-Tello C; Spitaleri D; McCombe P; Taylor B; Prevost J; Foschi M; Slee M; McGuigan C; Laureys G; Hijfte LV; de Gans K; Solaro C; Oh J; Macdonell R; Aguera-Morales E; Singhal B; Gray O; Garber J; Wijmeersch BV; Simu M; Castillo-Triviño T; Sanchez-Menoyo JL; Khurana D; Al-Asmi A; Al-Harbi T; Deri N; Fragoso Y; Lalive PH; Sinnige LGF; Shaw C; Shuey N; Csepany T; Sempere AP; Moore F; Decoo D; Willekens B; Gobbi C; Massey J; Hardy T; Parratt J; Kalincik T
Brain; 2023 Nov; 146(11):4633-4644. PubMed ID: 37369086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
